Investors comparing LCTX and VIR are effectively weighing two distinct biotechnology strategies. Lineage Cell Therapeutics is a small-cap developer of allogeneic (off-the-shelf) cell therapies for degenerative conditions, while Vir Biotechnology is a larger clinical-stage company spanning infectious diseases and emerging cancer immunotherapy. Both stocks are volatile, research-intensive names with limited commercial revenue, making their relative performance heavily dependent on clinical data, partnerships, and financing. This stock comparison is most relevant to growth-oriented and event-driven investors who are comfortable with binary clinical outcomes and who want to understand how market positioning, catalysts, and balance-sheet strength currently differentiate the two.
Lineage Cell Therapeutics (LCTX) develops allogeneic cell replacement therapies built on its AlloSCOPE manufacturing platform. Its most advanced asset, OpRegen, a retinal pigment epithelium (RPE) cell therapy for dry age-related macular degeneration, is partnered with Roche/Genentech. Additional programs include OPC1 for spinal cord injury and earlier-stage efforts such as ReSonance for hearing loss and COR1 for corneal disease. The company generates minimal revenue, recently in the low-single-digit millions per quarter, and reports consistent net losses.
In recent market activity, LCTX has trended lower, with the share price trading near the bottom of its 52-week range and a market capitalization of roughly $258 million. Despite this pullback, sell-side coverage remains optimistic, with a "Strong Buy" consensus and an average price target well above the current price. Cash and marketable securities of around $53 million support operations into 2028, but reliance on partnership milestones and future financing remains a key sensitivity for sentiment.
Vir Biotechnology (VIR) is a clinical-stage biopharmaceutical company focused on serious infectious diseases and cancer. Its lead hepatitis delta program pairs elebsiran and tobevibart, with Phase 3 ECLIPSE trials reporting topline data in the near term. In oncology, its PRO-XTEN platform underpins masked T-cell engagers — engineered proteins that direct immune cells toward tumor targets — including VIR-5500 (targeting PSMA in prostate cancer), partnered with Astellas, and earlier-stage HER2 and EGFR programs. A recent research collaboration with Gilead provided additional external validation.
Unlike LCTX, VIR has exhibited strong upward momentum in recent months, gaining substantially on a year-to-date basis and outperforming the broader market. The company ended its most recent quarter with roughly $900 million in cash and investments, plus additional proceeds from the Gilead agreement, extending its runway into the second half of 2028. Recent catalysts, including a U.S. FDA (Food and Drug Administration) Fast Track designation and proof-of-concept progress for VIR-5500, have reinforced positive sentiment.
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, but only a select group earns placement in the Trending AI Robots section. This curated list highlights the bots best aligned with current market conditions, each with its own trading style, strategy, timeframe, performance history, and basket of tickers. Because no single approach suits every environment, the page helps traders identify automated strategies whose recent performance and configuration are resonating with today's market. If you want to see how AI-driven strategies are currently approaching names like LCTX and VIR, explore the Trending AI Robots page.
The core contrast between these two stocks lies in scale, momentum, and catalyst timing. VIR is a substantially larger company with a diversified late-stage and preclinical pipeline, a nine-figure cash balance, and multiple near-term readouts. LCTX is smaller, more dependent on a single partnered program (OpRegen) and its manufacturing platform, and holds a much thinner cash reserve relative to its spending.
In terms of relative performance, VIR has shown stronger trend consistency and stability, while LCTX has experienced a downward drift despite bullish analyst targets. Risk factors also differ: LCTX faces financing and partnership-concentration risk, whereas VIR faces binary clinical risk concentrated in its hepatitis delta readouts and competitive scrutiny in oncology. Sector exposure is another trade-off — cell therapy versus T-cell engagers and antivirals — each carrying its own regulatory and reimbursement profile.
Based on observable factors such as trend consistency, stability, balance-sheet strength, and the density of near-term catalysts, Tickeron's AI would currently favor VIR. The stock's sustained positive momentum, larger cash runway, and multiple upcoming data events present a comparatively stronger market positioning than LCTX, which is trending lower and remains more dependent on a narrower set of catalysts. This assessment reflects a probabilistic, model-driven comparison of relative positioning rather than a definitive forecast, and conditions could shift as new data and market developments emerge.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LCTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 27 cases where LCTX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The 10-day moving average for LCTX crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +9.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in 159 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 125 of 156 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 66 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LCTX as a result. In 100 of 119 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for LCTX turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
LCTX moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.235) is normal, around the industry mean (3.498). P/E Ratio (-7.286) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. LCTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In 38 of the 41 cases the stock fell afterwards. This puts the odds of success at 90%.
The 10-day RSI Indicator for VIR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 53 cases where VIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIR as a result. In 76 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for VIR turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
VIR moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 125 of 158 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LCTX | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 73 | 41 | |
P/E GROWTH RATING 1..100 | 34 | 81 | |
SEASONALITY SCORE 1..100 | 90 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIR's Valuation (19) in the null industry is in the same range as LCTX (26). This means that VIR’s stock grew similarly to LCTX’s over the last 12 months.
VIR's Profit vs Risk Rating (100) in the null industry is in the same range as LCTX (100). This means that VIR’s stock grew similarly to LCTX’s over the last 12 months.
VIR's SMR Rating (96) in the null industry is in the same range as LCTX (98). This means that VIR’s stock grew similarly to LCTX’s over the last 12 months.
VIR's Price Growth Rating (41) in the null industry is in the same range as LCTX (73). This means that VIR’s stock grew similarly to LCTX’s over the last 12 months.
LCTX's P/E Growth Rating (34) in the null industry is somewhat better than the same rating for VIR (81). This means that LCTX’s stock grew somewhat faster than VIR’s over the last 12 months.
| LCTX | VIR | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 89% |
| Stochastic ODDS (%) | 3 days ago 83% | 3 days ago 83% |
| Momentum ODDS (%) | 3 days ago 84% | 3 days ago 83% |
| MACD ODDS (%) | 3 days ago 78% | 3 days ago 83% |
| TrendWeek ODDS (%) | 3 days ago 83% | 3 days ago 81% |
| TrendMonth ODDS (%) | 3 days ago 84% | 3 days ago 78% |
| Advances ODDS (%) | 7 days ago 76% | 7 days ago 76% |
| Declines ODDS (%) | 3 days ago 83% | 3 days ago 81% |
| BollingerBands ODDS (%) | 3 days ago 89% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 80% | 3 days ago 79% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LCTX’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LCTX’s TA Score shows that 4 TA indicator(s) are bullish while VIR’s TA Score has 3 bullish TA indicator(s).
LCTX (@Biotechnology) experienced а -10.33% price change this week, while VIR (@Biotechnology) price change was -18.43% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
LCTX is expected to report earnings on Mar 11, 2027.
VIR is expected to report earnings on Feb 25, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with EDIT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To LCTX | 1D Price Change % | ||
|---|---|---|---|---|
| LCTX | 100% | -7.64% | ||
| EDIT - LCTX | 44% Loosely correlated | +1.40% | ||
| MDGL - LCTX | 43% Loosely correlated | +0.51% | ||
| IMNM - LCTX | 41% Loosely correlated | +0.37% | ||
| FHTX - LCTX | 41% Loosely correlated | +0.98% | ||
| VIR - LCTX | 40% Loosely correlated | -17.82% | ||
More | ||||
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | -17.82% | ||
| BEAM - VIR | 55% Loosely correlated | -4.99% | ||
| SLDB - VIR | 53% Loosely correlated | -2.29% | ||
| DNLI - VIR | 52% Loosely correlated | -0.79% | ||
| CADL - VIR | 52% Loosely correlated | -26.10% | ||
| EDIT - VIR | 52% Loosely correlated | +1.40% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AAPB | 48.80 | 0.37 | +0.75% |
| GraniteShares 2x Long AAPL Daily ETF (AAPB) | |||
| IJUL | 36.15 | 0.03 | +0.08% |
| Innovator International Developed Power Buffer ETF - July (IJUL) | |||
| MHLA | 8.90 | N/A | N/A |
| Maiden Holdings Ltd | |||
| RDFI | 21.34 | -0.29 | -1.33% |
| Rareview Dynamic Fixed Income ETF (RDFI) | |||
| CRF | 5.69 | -0.20 | -3.40% |
| Cornerstone Total Return Fund | |||